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Background: Ranibizumab (Lucentis®) is a Fab-antibody fragment developed from Bevacizumab, a full-length
anti-VEGF antibody. Both compounds are used for treating age-related macular degeneration (AMD). The influence
of bevacizumab and ranibizumab on genes involved in signal transduction and cell signaling downstream of VEGF
were compared in order to detect possible differences in their mode of action, which are not related to their
Fab-antibody fragments.
Methods: Human umbilical vein cell lines (EA.hy926) and retinal pigment epithelial cells (ARP-19) were exposed to
oxidative stress. The cells were treated with therapeutic concentrations of bevacizumab (0.25 mg/mL) and
ranibizumab (125 mg/mL) for 24 hours prior to all experiments, and their effects on gene expressions were
determined by RT- PCR.
Results: After exposure to bevacizumab, more genes in the endothelial cells were up-regulated (KDR, NFATc2) and
down-regulated (Pla2g12a, Rac2, HgdC, PRKCG) compared to non-treated controls. After exposure to ranibizumab,
fewer genes were up-regulated (PTGS2) and down-regulated (NOS3) compared to controls. In comparison between
drugs, more genes were up-regulated (NFATc2 and KDR) and more were down-regulated (Pla2g12a, Pla2g1b,
Ppp3r2, Rac2) by bevacizumab than by ranibizumab. In RPE cells, NOS3 and PGF were up-regulated and Pla2g12b
was down-regulated after exposure to ranibizumab, while PIK3CG was up-regulated and FIGF was down-regulated
after exposure to bevacizumab, but the differences in gene expression were minor between drugs (PIK3CGand PGF
were down-regulated more by ranibizumab than by bevacizumab).
Conclusions: The different gene expressions after exposure to ranibizumab and bevacizumab in endothelial and
RPE cells may indicate a somewhat different biological activity of the two compounds.
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Age-related macular degeneration (AMD) is the leading
cause for legal blindness among the elderly in the indus-
trialized world. Pathological angiogenesis is the under-
lying cause of the exudative form of AMD.
VEGF-A is a potent endothelial cell mitogen, and recent
evidence indicates that it acts as an autocrine growth and
survival factor in VEGF-A-producing cells [1,2]. Several* Correspondence: shanigol2@walla.com
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reproduction in any medium, provided the orstudies suggest that it is a major mediator of angiogenesis
and vascular leakage in exudative AMD [3,4]. Inhibition
of VEGF-A activity has been a central theme in many
therapies under investigation. Several inhibitors have been
developed and are now used clinically.
In 2006, ranibizumab (Lucentis; Genentech, Inc., San
Francisco, CA, USA), an antibody fragment developed
against all fragments of VEGF, was approved by the
FDA for treating AMD following the MARINA [5] and
the ANCHOR [6] studies, which showed that ranibizumab
had a stabilizing effect in 90% of the patients and a benefi-
cial effect in 30%.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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sive. In contrast, bevacizumab, a full-length anti-VEGF anti-
body approved for use in colon cancer [7], costs much less
than ranibizumab.
Ocular use of bevacizumab is currently not FDA ap-
proved; nevertheless, it is widely used for treating AMD
[8-11]. Bevacizumab has been described in case reports
[8-10], retrospective studies [10,11], and controlled
prospective studies (CATT and IVAN trials) as effective
and well tolerated. To date, only limited experimental data
and studies comparing the effects of bevacizumab and
ranibizumab have been published. The comparative trials
CATTand IVAN evaluated the therapeutic efficacy of beva-
cizumab compared with ranibizumab, concluding that the
former was not inferior to the latter [12,13].
Despite the fact that ranibizumab and bevacizumab
share the same Fab-fragment blockage properties, they
are actually different molecules. Bevacizumab is produced
in Chinese hamster ovary (CHO) cells from the expression
plasmids VID5.ID.LLnspeV.xvegf36HC.LC. The resulting
antibody is produced from the G7 clone as a 149-kDa
full-length IgG1 antibody composed of two 214-residue
light chains and two 453-residue heavy chains. Each
light chain is covalently linked to a heavy chain and the
two heavy chains are covalently bonded. The resulting
bevacizumab antibody contains 93% human amino acid
sequence [14,15].
Ranibizumab was developed in an effort to obtain higher
affinity variants of Fab-12 with improved potency and effi-
cacy [16]. Although bevacizumab was derived from Fab-12,
ranibizumab was derived from an in vitro CDR mutation
and affinity selection from a different humanized anti-
VEGF Fab variant, known as MB1.6 [17,18]. Ranibizumab
is produced as a 48 kDa Fab in Escherichia coli from the ex-
pression plasmid pY0317. The heavy and light chains fold
into their native conformation following secretion into the
bacteria’s periplasmic space and are covalently linked. The
resulting Fab-Y0317 is known as ranibizumab [19,20].
It has been shown previously that the two molecules act
differently and posses' different pathway activities which
may be unrelated to their anti-VEGF activities [21-23].
As bevacizumab and ranibizumab differ in their mo-
lecular composition and physiologic properties, the
present studycomparedVEGFinhibitors in termsof their
effects on genes involved in signal transduction and cell
signalingdownstreamofVEGF.
The genes selected are all genes expressed downstream
the VEGF pathway in the cell after receptor dimerization
and autophosphorylation.
The expressions of genes directly mediating VEGF
signaling were analyzed to detect differences in mo-
lecular pathways when both compounds are applied.
The chosen model was designed to compare the effects
of VEGF inhibitors on specific genes expressed in theangiogenesis/vasculogenesis process in both RPE and
endothelial cells.
Cellular damage resulting from oxidative stress in both
endothelial and RPE cells plays a causative role in AMD
[3]. Oxidative stress-induced RPE cell apoptosis has been
proposed as a major pathophysiological mechanism of
AMD [3,22-24]. In particular, RPE cell apoptosis is an im-
portant feature of the advanced form of dry AMD [3,25]
Thus, oxidative stress induces VEGF-A expression from the
RPE and also RPE death [3,22], suggesting a role for such
stress in both neovascular and advanced dry AMD.
The effects on gene expression were examined using a
model of ischemia (12 hours in a hypoxic chamber) to
mimic significant stress imposed upon the cells in neo-
vascular AMD in real time.
Methods
Cell culture
EA.hy926 cells (a human umbilical vein cell line) were
seeded at 100,000/cm [2] in T-75 cm [2] flasks containing
DMEM with 15 Mm Hepes buffer, 10% fetal bovine serum,
2 mM L-glutamine solution and 10% pen-strep at 37°C for
1 week. Serum was withdrawn in DMEM+1% bovine
serum albumin for 3 days to make the cells quiescent.
ARPE-19 cells were seeded on 1*10 [6]/10 cm plates
containing DMEM with 10% fetal bovine serum,
1% L-glutamine solution, and 10% pen-strep at 37°C for
1 week, and serum was withdrawn in DMEM+ 1% bovine
serum albumin for 3 days to make the cells quiescent.
Exposure to bevacizumab and ranibizumab
Before all experiments, both cell lines were treated for
12 hours in a hypoxic chamber (exposure to less than 2%
oxygen in the chamber). Therapeutic dosages of both beva-
cizumab and ranibizumab (0.25 mg/mL and 0.125 mg/mL,
respectively) were then added to the cell lines. These con-
centrations were prepared using serial dilutions of the drug
in the respective serum-free culture medium. The solution
of the drug mixed with media was then directly added to
the cells in order to obtain a uniform concentration of drug
throughout the well of the tissue culture plate. In addition
to bevacizumab and ranibizumab, the cells were also treated
with 10 ng/ml hVEGF (PeprotechInc, Rocky Hill, NJ, USA).
Control groups
All experiments were compared to controls. Controls were
cells that had been treated with human VEGF (hVEGF)
alone and no bevacizumab or ranibizumab.
RNA production
After 48 hours of exposure to either ranibizumab or bev-
acizumab, the total cellular RNA was isolated from the
cells by a QiagenRNeasy® Mini Kit (Catalog # 74104) ac-
cording to the manufacturer's instructions. RNA samples
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Mini Kit, Catalog # 74104). RNA quantification was per-
formed with spectrophotometry (ND-1000; NanoDrop
Products, Thermo Fisher Scientific, Wilmington, DE), after
which 250 ng of total RNA was analyzed by agarose gel
electrophoresis to confirm integrity. The resultant RNA
was stored at -80°C.
The RNA was reverse transcribed using the RT [2] First
Strand Kit (Qiagen).
Real-time quantitative (q) RT-polymerase chain reaction (PCR)
A SAB biosciences RT [2] Profiler PCR Array assay
(Qiagen) was performed according to the manufacturer's
instructions, using syber green [26].
The RT array included five controls for housekeeping
genes, one control for genomic DNA and three reverse
transcription controls (no RNA loaded).three positive RNA
controls were also present. PCR was performed on an ABI
Prism 7700 Sequence Detector (©2008 Applied Biosystems.
All rights reserved. Applera, Applied Biosystems). The data
were analyzed using the web-based software RT2 Profiler
PCR Array data analysis tool, (Qiagen). The ΔΔCt method
was used for data analysis. Specifically, fold-changes for
each gene were calculated as difference in gene expression
between bevacizumab exposure and control, and between
ranibizumab exposure and control. A positive value indi-
cated gene up-regulation and a negative value indicated
gene down-regulation.
Statistical analysis
Each experiment was independently repeated at least
twice (as recommended by the manufacturers guidelines
for statistical significance). Genes with greater than 2.5
fold change in expression compared to control were
identified as significant (p < 0.05).Only results that showed
a relatively high (>30) average threshold cycle of a gene in
either the control or the test sample, and a reasonably low
(<30) average threshold cycle in the other sample were in-
cluded. Data that demonstrated the gene’s expression was
relatively low in one sample and reasonably detected in
the other sample suggested that the actual fold-change
value was at least as large as the calculated and reported
fold-change result. The results that fitted this formula
were graded “A”. Results that were graded “B” indicated
that the gene’s average threshold cycle was relatively high
(>30), implying that its expression level was relatively low
in both the control and test samples, and that the P value
for the fold-change was relatively high (P > 0.05). All ex-
periments were repeated at least twice. The list of genes
examined is summarized in Table 1.
Results
A comparison of the various gene expression patterns of
RPE cells after exposure to both anti-VEGF agents andexposure solely to hcVEGF (control) are presented in
Tables 2,3 and 4 and Figure 1A-C. Several genes of
RPE cells that were treated with bevacizumab were
over-expressed compared to controls (MAPK genes,
the SPHK gene and the VEGFA gene), while others
(the KDR, NOS, PIK3R and PLA2Ggenes) were under-
expressed. When the RPE cells were treated with ranibizu-
mab, the NFATC, MAPK, SPHK and VEGFA genes were
up-regulated, whereas the KDR and NOS3 genes were
under-expressed compared to controls. Only the PGF and
PIK3CG genes were down-regulated in the RPE cells that
had been treated with bevacizumab compared to when
they had been treated with ranibizumab.
Comparisons of the various gene expressions of endo-
thelial cells after exposure to bevacizumab, ranibizumab,
and controls are shown in Table 5 and Figure 1D. After
exposure to ranibizumab, PTGS2 was up-regulated com-
pared to controls (hVEGF), while NOS3 expressions were
down-regulated.
After exposure to bevacizumab, different genes were
up- and down-regulated compared to controls (Table 6
and Figure 1E, F). The KDR gene was over-expressed
and the FIGF gene was under-expressed. However, in cells
treated with ranibizumab, only the NOS3 gene expression
was down-regulated compared to controls. Comparison of
the two treatment arms revealed that the KDR gene was
significantly up-regulated in the cells treated with bevaci-
zumab compared to those treated with ranibizumab, and
that the PRKCG gene was down-regulated.
Discussion
The results of the present study suggest that gene expres-
sions differ after exposure to ranibizumab and bevacizumab
in RPE and endothelial cell lines. This finding may indicate
that although they both block the VEGF signaling pathway,
they probably do so in a somewhat different biological
mechanism, or through different transmitters.
RPE cells exposed to either bevacizumab or ranibizumab
exhibit different gene expression as compared to controls.
Mainly MAPK and VEGFA are over-expressed when
treated with either bevacizumab or ranibizumab compared
to controls, and the expression of KDR and NOS genes was
down-regulated. However, when the two treatment arms
were compared (bevacizumab compared to ranibizumab),
no major differences in gene expression are noted
(besides PGF and PIK3CG). Both gene expressions
play a role in the VEGF receptor dimerization and au-
tophosphorylation, and play a crucial role in the VEGFA
mitogenic signaling pathway.
In endothelial cells, the situation was somewhat different.
No major gene expression was noted when comparing both
treatment arms to control; however, when comparing beva-
cizumab to ranibizumab, major differences in gene expres-
sions were noted (KDR and NOS3 were up-regulated and
Table 1 Positions of genes and genes symbol
Position Symbol B11 MAPK12
A01 AKT1 B12 MAPK13
A02 AKT2 C01 MAPK14
A03 AKT3 C02 MAPK3
A04 ARNT C03 MAPKAPK2
A05 BAD C04 MAPKAPK3
A06 CASP9 C05 NFAT5
A07 CAV1 C06 NFATC1
A08 CDC42 C07 NFATC2
A09 FIGF C08 NFATC3
A10 FLT1 C09 NFATC4
A11 FLT4 C10 NOS3
A12 GRB2 C11 NRAS
B01 HIF1A C12 NRP1
B02 HRAS D01 NRP2
B03 HSP90AA1 D02 PDGFC
B04 HSPB1 D03 PGF
B05 KDR D04 PIK3CA
B06 KRAS D05 PIK3CB
B07 MAP2K1 D06 PIK3CD
B08 MAP2K2 D07 PIK3CG
B09 MAPK1 D08 PIK3R1
B10 MAPK11 D09 PIK3R2
D10 PIK3R3 F10 PRKCG
D11 PIK3R5 F11 PTGS2
D12 PLA2G10 F12 PTK2
E01 PLA2G12A G01 PXN
E02 PLA2G12B G02 RAC1
E03 PLA2G1B G03 RAC2
E04 PLA2G2A G04 RAF1
E05 PLA2G2D G05 SH2D2A
E06 PLA2G2E G06 SHC2
E07 PLA2G2F G07 SPHK1
E08 PLA2G3 G08 SPHK2
E09 PLA2G4A G09 SRC
E10 PLA2G4B G10 VEGFA
E11 PLA2G5 G11 VEGFB
E12 PLA2G6 G12 VEGFC
F01 PLCG1 H01 B2M
F02 PLCG2 H02 HPRT1
F03 PPP3CA H03 RPL13A
F04 PPP3CB H04 GAPDH
F05 PPP3CC H05 ACTB
F06 PPP3R1 H06 HGDC
Table 1 Positions of genes and genes symbol (Continued)
F07 PPP3R2 H07 RTC
F08 PRKCA H08 RTC
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a calcineurin/nuclear factor of activated Tcells c2 (NFATc2)
pathway and has displayed an anti-apoptotic role in melan-
oma cells [27].
VEGF is a heparin-binding homodimeric glycoprotein
that acts via endothelial-specific receptor tyrosine kinases,
VEGFR1 (Flt1), VEGFR2 (KDR/Flk1), and VEGFR3 (Flt4)
[28]. In addition to VEGFA, the VEGF family of growth fac-
tors contains five other known members, namely placenta
growth factor (PIGF), VEGFB, VEGFC, VEGF-D and viral
VEGF homologs. Disruption of the genes encoding
either VEGF or any of the three receptors of the VEGF
family results in embryonic lethality due to failure of
blood vessel development.
VEGFR2 is the main signal transducing VEGF receptor
for angiogenesis and mitogenesis of endothelial cells.
After receptor dimerization and autophosphorylation,
several other signal transduction molecules are activated
either directly or by indirect mechanisms [29].Table 2 Fold change of gene expression in retinal
pigment epithelial cells exposed to bevacizumab







MAPK3 Mitogen-activated protein kinase 3 19.7066 A
NFATC2 nuclear factor of activated T-cells 5.2333 A
NRP1 Neuropilin 1 7.0536 A




NOS3 Nitric oxide synthase -170.2534 A
NRP2 Neuropilin 2 -6.2684 A
PIK3R3 Phosphoinositide-3-kinase,





PLA2G2A Phospholipase A2, group IIA -21.5369 B
PLA2G2D Phospholipase A2, group IID -40.967 B
PLA2G2E Phospholipase A2, group IIE -31.6041 B
PLA2G2F Phospholipase A2, group IIF -212.0617 B
Table 3 Fold change of gene expression in retinal
pigment epithelial cells exposed to ranibizumab







NOS3 Nitric oxide synthase -293.5515 A
KDR Kinase insert domain receptor -5.0041 A
MAPK3 Mitogen-activated protein kinase 3 +20.0674 A




SPHK1 Sphingosine kinase 1 +28.9047 A
PLA2G2E Phospholipase A2, group IIE -26.829 B
PLA2G2F Phospholipase A2, group IIF -123.5516 B
PLA2G2A Phospholipase A2, group IIA
(platelets, synovial fluid)
-12.4228 B
PLA2G1B Phospholipase A2, group IB -89.4568 B
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cells treated with either bevacizumab or ranibizumab.
A differential involvement of mitogen activated protein
kinases (MAPK) has been previously shown to be in-
volved in VEGF expression and regulation [22], as P 38
is involved in constitutive and oxidative stress regulated
VEGF expression. This pathway conveys the VEGF sig-
nal to microfilaments inducing rearrangements of the
actin cytoskeleton that regulate endothelial cell migra-
tion by modulating the activation of MAPK2/3 (MAP
kinase activated protein kinase-2/3) and phosphoryl-
ation of the F-actin polymerization modulator, HSP27
(heat shock protein-27).
KDR and NOS genes were both down-regulated in RPE
cells exposed to both anti-VEGF agents. Both genes have
key roles in mediating VEGF activity in increasing the pro-
liferation and permeability of capillary endothelial cells.
Increasing the proliferation and permeability of endothe-
lial cells may produce unwanted side effects, such as tumor
angiogenesis, vascular leakage, edema, and inflammation
[30]. In endothelial cells, the VEGF-Flk1/KDR signal system
is a very important generator of NO (nitric oxide) through
the activation of its downstream effectors PI3K, Akt kinase
and eNOS (endothelial NO synthase).
Their role in RPE cells has also been previously in-
vestigated. KDR has been proposed to trasmit protect-
ive signaling against oxidant induced cell death in bothTable 4 Fold change of gene expression in retinal pigment ep
ranibizumab
Gene symbol Gene name
Pgf placental growth factor
Pik3cg phosphoinositide-3-kinase, catalytic, gamma polnormal conditions and disease states such as AMD
[31]. It was also suggested to be involved in autokrine
VEGF regulation [32].
Both genes were statistically significantly down-regulated
after treatment with both anti-VEGF agents in RPE cell,
perhaps indicating that both anti-VEGF agents block the
angiogenesis and vascular leakage through these two genes.
Interestingly, both KDR and NOS3 genes were up-
regulated in endothelial cells treated with bevacizumab
compared to ranibizumab. This finding may suggest that
there is a somewhat different mechanism of action between
the two compounds in endothelial cells specifically.
Early preclinical [33,34] and clinical [35-37] studies
have implicated VEGF as a major factor in the patho-
genesis of neovascular eye diseases, supporting the ra-
tionale for further investigation of the therapeutic potential
of VEGF-targeted agents. VEGF-based therapies for a variety
of human pathological situations that are associated
with aberrant endothelial proliferation and aberrant neo-
vascularization include the use of neutralizing antibodies
against VEGFA or VEGFR2, antisense oligonucleo-
tides, negative regulatory peptides, soluble receptors,
and ATP analogs to inhibit the kinase activity of
VEGFR [17]. Interference with VEGF function has,
therefore, become a subject of major interest for drug
development to block angiogenesis, and the targeting
of the VEGF signaling pathway may be of therapeutic
importance for many diseases.
Conclusions
The present study describes the preliminary results of
altered gene expression downstream of the VEGF sig-
nal pathway when comparing ranibizumab treatment
to bevacizumab treatment in both RPE and endothelial
cell lines. Our results indicate a somewhat different
biological activity of the two compounds that need to
be further explored.
This study has several limitation; first of being only
based on RNA analysis (no Confirmation of results at
the protein level) and results at the RNA level are often
not replicated at the protein level.
The second limitation is that the study relies on a
commercial custom-based Q-PCR assay, and the test
genes were all genes in the VEGF pathway that were
present on the kit. It could be that other more complex
involvement of genes expression is involved and was not




Figure 1 Heatmap of the altered expression of gens in the different groups compared. A. Heatmap of the results showing genes with
significantly altered transcription levels as a function of exposure to bevacizumab versus non-treated control in RPE cells. B. Heatmap of the
results showing ranibizumab versus human VEGF treated control in retinal pigment epithelial cells. C. Heatmap of the results showing
bevacizumab versus ranibizumab in RPE cells. D. Heatmap of the results showing bevacizumab versus human VEGF-treated control in endothelial
cells. E. Heatmap of the results showing ranibizumab versus human VEGFreated control in endothelial cells. F. Heatmap of the results showing
bevacizumab versus ranibizumab in endothelial cells.
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cause we have examined AMD model, and because of
the complexity of the analysis of gene array, we have
chosen not to further complex our statistics by adding
non starved and non hypoxic cells.Table 5 Fold change of gene expression in endothelial
cells exposed to Bevacizumab or Ranibizumab compared
to control
Gene symbol Gene name Bevacizumab/
control
Grade
KDR kinase insert domain receptor + 6.3173 A




PLA2G5 Phospholipase A2, group V -3.928 B
PRKCG Protein kinase C gamma -5.0676 B
Gene symbol Gene name Ranibizumab/
control
Grade
NOS3 nitric oxide synthase 3 -14.8 AAnother major limitation of the study is the non con-
ventional use of statistical analysis. We were unable to
perform column analysis like t-testing or one way
ANOVA because of the small number of samples ob-
tained and the lack of normal distribution. In further
studies, our results must be validated when using a lar-
ger scale analysis.Table 6 Fold change of gene expression in endothelial
cells exposed to bevacizumab compared to endothelial
cells exposed to ranibizumab
Gene symbol Gene name Bevacizumab/
ranibizumab
Grade
KDR Kinase insert domain receptor +5.547 A
NOS3 Nitric oxide synthase
3 (endothelial cell)
+86.3228 A
NFATC2 Nuclear factor of
activated T-cells
-3.3708 A
PLA2G2E Phospholipase A2, group IIE -11.1207 B
PRKCG Protein kinase C, gamma -5.3751 B
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